Lacosamide Aurobindo

Lacosamide, the active ingredient in Lacosamide Aurobindo, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures with or without secondary generalization in adults.

GNH USA supplies Lacosamide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant used as adjunctive therapy for focal seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. Focal seizures with secondary generalization: provides additional seizure control in adults. Adjunctive therapy for epilepsy: improves overall seizure management when combined with other approved agents.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: generalized tiredness. - Blurred vision: temporary visual disturbance. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Suicidal ideation: emergence of depressive thoughts. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic enzyme elevation: significant increase in liver function tests. - Aseptic meningitis: rare inflammatory response of the meninges.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Renal impairment: adjust dose based on creatinine clearance. Hepatic impairment: monitor liver function and consider dose modification. Cardiac conduction disorders: obtain baseline ECG and monitor PR interval. Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. Concomitant CNS depressants: observe for additive sedation or respiratory depression. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma concentrations. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide efficacy. - Other sodium‑channel blockers (e.g., lamotrigine, phenytoin): increase risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Additional antiepileptic drugs: may require dose adjustments to maintain therapeutic balance. - Alcohol or CNS depressants: enhanced sedation or respiratory depression. - Hormonal contraceptives: possible reduction in contraceptive effectiveness, consider alternative methods.